Pharmacoeconomic review report Empagliflozin and Metformin fixed-dose combination (Synjardy) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Drug interactions--Handbooks, manuals, etc.

Drug interactions.

Physical Description:

1 online resource (16 pages)

Other Title:

Pharmacoeconomic review report Empagliflozin and Metformin fixed-dose combination

Place of Publication:

Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017.

Summary:

Empagliflozin (EMPA)/metformin (MET) fixed-dose combination (FDC) tablet (Synjardy) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM) inadequately controlled on MET alone, MET and a sulfonylurea (SU), MET and pioglitazone (PIO), or MET and insulin; or when EMPA and MET are already being co-administered as separate tablets with or without an SU, PIO, or insulin. The manufacturer is seeking reimbursement for adult patients with T2DM who are already stabilized on therapy with MET and EMPA, to replace the individual components.

Notes:

Description based on publisher supplied metadata and other sources.